Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis

University Medical Center Groningen38 enrolled

Overview

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalaninepositron emission tomography (18F-DOPA-PET) scan. This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan retrospectively.

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) scan. This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan in retrospect.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neuroendocrine Tumors

Interventions

Metastasized intestinal NETOTHER

This is an observational study

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age ≥18 years * diagnosis of intestinal NET diagnosed by a dedicated NET specialist * more than one positive lesion on the 18F-DOPA-PET scan. * available CT-scan within 6 months before or after the 18F-DOPA-PET-scan. Exclusion Criteria: * no clinical data available at the UMCG, besides the results of the DOPA PET scan.

Locations (1)

University Medical Center Groningen

Groningen, Netherlands

Outcomes

Primary Outcomes

tracer uptake in tumor lesions within patients with intestinal NET

The difference in tracer uptake of tumor lesions within patients with intestinal NET measured on a 18F- DOPA-PET scan.

Time frame: at the day of scan

Secondary Outcomes

tracer uptake in tumor lesions within patients with intestinal NET adjusted for uptake of background organ

The difference in tracer uptake of tumor lesions adjusted for uptake of background organ within patients with intestinal NET measured on a 18F- DOPA-PET scan.

Time frame: at the day of scan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.